Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus

References

• ChiltonRWyattJNandishSOliverosRLujanMCardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagons-like peptide-1-based therapiesAm J Med2011124S35S5321194579
   PubMed Web of Science ®Google Scholar
• FrühbeckGOverview of adipose tissue and its role in obesity and metabolic disordersMethods Mol Biol200845612218516549
   PubMedGoogle Scholar
• HansenEJajriTAbdumradNNIs all fat the same? The role of fat in the pathogenesis of the metabolic syndrome and type 2 diabetes mellitusSurgery200613971171616782424
   PubMed Web of Science ®Google Scholar
• LorberDGLP-1 receptor agonists: effects on cardiovascular risk reductionCardiovasc Ther20133123824923865382
   PubMed Web of Science ®Google Scholar
• BlondeLRussell-JonesDThe safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studiesDiabetes Obes Metab20093263419878259
   PubMed Web of Science ®Google Scholar
• HanTSWuFCLeanMEObesity and weight management in the elderly: a focus on menBest Pract Res Clin Endocrinol Metab20132750952524054928
   PubMed Web of Science ®Google Scholar
• KaurPMishraSKMithalASaxenaMMakkarASharmaPClinical experience with liraglutide in 196 patients with type 2 diabetes from a tertiary care center in IndiaIndian J Endocrinol Metab201418778224701434
   PubMedGoogle Scholar
• AstrupARössnerSVan GaalLEffects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled studyLancet20093741606161619853906
   PubMed Web of Science ®Google Scholar
• FlintARabenAAstrupAHolstJJGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humansJ Clin Invest19981015155209449682
   PubMed Web of Science ®Google Scholar
• VerdichCFlintAGutzwillerJPA meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humansJ Clin Endocrinol Metab2001864382438911549680
   PubMed Web of Science ®Google Scholar
• NiswenderKPi-SunyerXBuseJWeight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programmeDiabetes Obes Metab201315425422862847
   PubMed Web of Science ®Google Scholar
• JanssenIBaumgartnerRNRossRRosenbergIHRoubenoffRSkeletal muscle cutpoints associated with elevated physical disability risk in older men and womenAm J Epidemiol200415941342114769646
   PubMed Web of Science ®Google Scholar
• FrisanchoARNew standards of weight and body composition by frame size and height for assessment of nutritional status of adults and the elderlyAm J Clin Nutr1984408088196486088
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationBantleJPWylie-RosettJAlbrightALNutrition recommendations and interventions for diabetes: a position statement of the American Diabetes AssociationDiabetes Care200831S61S7818165339
   PubMed Web of Science ®Google Scholar
• DavisNJEmereniniAWylie-RosettJObesity management: physician practice patterns and patient preferenceDiabetes Educ20063255756116873593
   PubMed Web of Science ®Google Scholar
• HaberGBHeatonKWMurphyDBurroughsLFDepletion and disruption of dietary fibre. Effects on satiety, plasma-glucose, and serum-insulinLancet1977267968271495
   PubMed Web of Science ®Google Scholar
• NathanDMKuenenJBorgRZhengHSchoenfeldDHeineRJA1c-Derived Average Glucose Study GroupTranslating the A1C assay into estimated average glucose values. Translating the A1C assay into estimated average glucose valuesDiabetes Care2008311473147818540046
   PubMed Web of Science ®Google Scholar
• HaffnerSMKennedyEGonzalezCSternMPMiettinenHA prospective analysis of the HOMA model. The Mexico City Diabetes StudyDiabetes Care199619113811418886564
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final reportCirculation20021063143342112485966
   PubMed Web of Science ®Google Scholar
• FitzmauriceGMLairdNMWareJHApplied Longitudinal AnalysisHoboken, NJWiley-Interscience2004
   Google Scholar
• PinheiroJBatesDDebRoySSarkarDR Development Core Teamnlme: Linear and Nonlinear Mixed Effects ModelsR package version 320131108
   Google Scholar
• Development Core TeamR: A Language and Environment for Statistical ComputingVienna, AustriaR Foundation for Statistical Computing2012
   Google Scholar
• ChangAMJakobsenGSturisJThe GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single doseDiabetes2003521786179112829647
   PubMed Web of Science ®Google Scholar
• HarderHNielsenLTuDTAstrupAThe effect of liraglutide, a longacting glucagon-like peptide 1 derivative, on glycaemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetesDiabetes Care2004271915192115277417
   PubMed Web of Science ®Google Scholar
• De WitHMVervoortGMJansenHJde GrauwWJde GalanBETackCJLiraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)Diabetologia2014571812181924947583
   PubMed Web of Science ®Google Scholar
• FlintAKapitzaCHindsbergerCZdravkovicMThe once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patientsAdv Ther20112821322621340616
   PubMed Web of Science ®Google Scholar
• JendleJNauckMAMatthewsDRWeight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissueDiabetes Obes Metab2009111163117219930006
   PubMed Web of Science ®Google Scholar
• InoueKMaedaNKashineSShort-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetesCardiovasc Diabetol20111010922132774
   PubMed Web of Science ®Google Scholar
• NauckMFridAHermansenKEfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 studyDiabetes Care200932849018931095
   PubMed Web of Science ®Google Scholar
• LiCJYuQYuPChanges in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patientsCardiovasc Diabetol2014133624498905
   PubMed Web of Science ®Google Scholar
• GarberAHenryRRatnerRLiraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trialLancet200937347348118819705
   PubMed Web of Science ®Google Scholar
• FujishimaYMaedaNInoueKEfficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetesCardiovasc Diabetol20121110722973968
   PubMed Web of Science ®Google Scholar
• KuhadiyaNDMalikRBelliniNJLiraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitusEndocr Pract20131996396723807520
   PubMed Web of Science ®Google Scholar
• FlintAKapitzaCZdravkovicMThe once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatmentDiabetes Obes Metab20131595896223551925
   PubMed Web of Science ®Google Scholar
• HorowitzMFlintAJonesKLEffect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetesDiabetes Res Clin Pract20129725826622446097
   PubMed Web of Science ®Google Scholar
• Rodriquez de FonsecaFNavarroMAlvarezEPeripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese ratsMetabolism20004970971710877194
   PubMed Web of Science ®Google Scholar
• Van BloemendaalLTen KulveJSla FleurSEIjzermanRGDiamantMEffects of glucagon-like peptide 1 on appetite and body weight: focus on the CNSJ Endocrinol2014221T1T1624323912
   PubMed Web of Science ®Google Scholar
• AbbottCRMonteiroMSmallCJThe inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathwayBrain Res2005104412713115862798
   PubMed Web of Science ®Google Scholar
• PiotrowskiKBeckerMZugwurstJCirculating concentrations of GLP-1 are associated with coronary atherosclerosis in humansCardiovasc Diabetol20131211723953602
   PubMed Web of Science ®Google Scholar
• PlutzkyJGarberAJFalahatiAToftADPoulterNRThe once-daily human GLP-1 analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trialsEur Heart200930917
   Web of Science ®Google Scholar
• PonzaniPLong-term effectiveness and safety of liraglutide in clinical practiceMinerva Endocrinol20133810311223435446
   PubMed Web of Science ®Google Scholar
• InoueKMaedaNFujishimaYLong-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational studyDiabetol Metab Syndr201469525237400
   PubMed Web of Science ®Google Scholar